MAX IV pairs up with Sprint Bioscience, a listed drug development company, in a new project to improve how companies can benefit from new, faster X-ray fragment screening experiments, while still protecting their valuable information during analysis at FragMAX. Recently, the project was granted with 500 000 SEK from Sweden’s innovation agency Vinnova. More or
The spring call for proposals for eight beamlines at MAX IV closed 19 March with a total of 228 proposals from 28 countries. The number of applications is on par with proposals received when the former MAX-lab peaked, which shows that the demand from users is high as well as is their confidence in getting excellent tools
The samples at BioMAX beamline are very sensitive biomolecule crystals. It could, for example, be one of the many proteins you have in your body. They only last for a short time in the intense X-ray light before being damaged and needs to be placed exactly right before the researchers switch on the beam.
The MX-group of MAX IV has been successfully to be a partner in a large UK doctoral training programme. The funding was announced last month by the Engineering and Physical Sciences Research Council (EPSRC) in the UK which will invest £446 million in skill development as well as partnering with industry for an additional
Uwe Müller and Gustavo Lima were recently awarded funding from Vetenskapsrådet for their project FragMAX. This project runs in collaboration with two Swedish companies, Astra Zeneca and SAROMICS BioStructures and the Lund University Protein Production Platform LP3. FragMAX aims to establish a fragment screening facility at MAX IV, which is an important tool for industrial
Image: The SESAME Synchrotron in Jordan The Swedish Institute is funding scholarships for training for researchers related to the SESAME synchrotron in Jordan to come to MAX IV for 3 – 6 months. The first researcher to be awarded a grant is now in Lund and well underway with her training. Saima Rasheed is an
A new EU project in the program area Öresund-Kattegatt-Skagerak (ÖKS) has been approved. The Hanseatic League of Science (HALOS) will build a unique collaboration between Hamburg and South-West Scandinavia, bring together the four unique research facilities MAX IV, ESS, DESY and European XFEL, and create a centre for integrated, world-leading Life Science innovation and research.
The macromolecular crystallography beamline BioMAX have for the first time been running their sample changer on a regular basis. The robot has been changing 320 samples for four user groups within its first two weeks of operation. At a macromolecular crystallography beamline, the samples are biological molecules. One example is the proteins which are the
“BioMAX serial crystallography setup using a High Viscosity Extrusion (HVE) injector specially designed for the BioMAX endstation by Bruce Doak of the Max Planck Institute for Medical Research, Heidelberg, and fabricated at that institute.” BioMAX has successfully performed the first serial crystallography experiments at the beamline. This new method is performed at room temperature
The first day of user data collections at the BioMAX beamline at MAX IV has now resulted in the first scientific publication and the first three-dimensional structure of a protein deposited in the international protein data bank. The first publication presents a new method for solving protein structures of challenging samples but the method can